Research-based biopharmaceutical companies are active partners in some of the largest and boldest health initiatives to explore new and effective ways of increasing access to health care in the developing world.
These companies are committed to fighting devastating diseases such as AIDS, tuberculosis (TB) and malaria through the research and development (R&D) of new drugs, diagnostics and vaccines.

One billion people suffer from preventable,
treatable diseases around the world

Statement by Dr. Paul Antony, medical director
Global Health Progress

The Group of Eight leaders set a five-year deadline to provide 60 billion dollars to fight disease in Africa, but activists said the pledge meant little to the continent's poor.

Read the story from AFP >>

This New York Times editorial discusses an important bill to increase American spending on AIDS, malaria and tuberculosis around the world.

Read the New York Times story >>

Drug researcher W. Ripley Ballou remembers the moment he realized that GlaxoSmithKline Plc's experimental malaria vaccine might save millions of lives.

Read the story by Andrea Gerlin on Bloomberg.com >>

The U.S. embassy in Vietnam on Tuesday announced that President's Emergency Plan for AIDS Relief will allocate $1.4 million to three HIV/AIDS initiatives in Vietnam, the Thanh Nien News reports.

Read the story from The Kaiser Network >>

The annual meeting of National task forces for Onchocerciasis (river blindness) Control is underway to review progress in the battle against one of the neglected tropical diseases.

Read the story from Afrique en Lingne >>

President George W. Bush urged Congress on Wednesday to approve funds to fight AIDS in Africa and other countries, and said the issue was high on his agenda for a Group of Eight summit in Japan.

Read the full story from Reuters >>

People with HIV in the developed world are no more likely to die in the first five years following infection than men and women in the general population.

Read the full story by Michael Kahn >>

People in low-resource countries with multidrug-resistant TB will a diagnosis in two days instead of the standard two to three months thanks to two new initiatives unveiled by the World Health Organization (WHO), the Stop TB Partnership, UNITAID and the Foundation for Innovative New Diagnostics (FIND).

Read the whole story from HPN Online >>

Pages